This author has not written his bio yet.
But we are proud to say that Administrator contributed 2431 entries already.
Challenges transitioning new clinicians from academic training to professional practice tops ECRI’s 2024 list of top 10 patient safety concerns for 2024 released by one of the nation’s largest patient safety organizations. ECRI researchers compiled the report by drawing on evidence-based research, data, and expert insights.
Bristol Myers Squibb’s Opdivo was recently granted FDA approval in combination with cisplatin and gemcitabine as a first-line treatment for metastatic urothelial carcinoma. With this approval, Opdivo positions itself to compete with Merck & Co’s immune checkpoint inhibitor Keytruda in combination with Astellas and Pfizer’s Padcev, a nectin-4-directed antibody-drug conjugate, according to GlobalData.
On Friday the agency approved a label expansion for Wegovy based on a supplemental New Drug Application for the indication of reducing risks of major adverse cardiovascular events including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease.
The Empower system is the first of its kind, award-winning operating system, built specifically for the health marketplace, and designed to unlock the power of data-driven media strategy and seamless execution within a transparent and collaborative interface.
Use of GLP-1 receptor agonists, or GLP-1s, is skyrocketing in the United States, with more than nine million prescriptions for Ozempic, Wegovy, Mounjaro, and similar diabetes and obesity drugs written during the last three months of 2022 alone. Zepbound weekly prescriptions hit 25,000 in December 2023, just one month after it was approved to treat obesity. These drugs may make oral birth control pills less effective at certain points in the dosing schedule, making an unintended pregnancy more likely.
The agency has elevated employees to senior art directors and senior medical strategists.
The strategic hires continue to underscore Coefficient Health’s rapid growth and ongoing commitment to providing clients with the highest level of service and expertise in navigating the ever-evolving healthcare landscape.
The Dexcom Stelo Glucose Biosensor System is intended for anyone 18 years and older who does not use insulin, such as individuals with diabetes treating their condition with oral medications, or those without diabetes who want to better understand how diet and exercise may impact blood sugar levels.
SFC Group’s acquisition of CareContent underscores its unwavering dedication to delivering compelling content and creative marketing solutions to its clients. By adding CareContent’s talented team members and assets, SFC Group is poised to redefine the standards of excellence in healthcare marketing and usher in a new era of growth and opportunity.
Novo Nordisk expects to file for regulatory approvals of a label expansion for Ozempic in the US and EU in 2024. The detailed results from FLOW will be presented at a scientific conference in 2024.